ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cost-Effectiveness of CT Screening in the National Lung Screening Trial

Wednesday, November 5, 2014

Submitted by

Mark Ferguson

Source

Source Name: New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1312547?query=TOC

Author(s)

William C. Black, Ilana F. Gareen, Samir S. Soneji, JoRean D. Sicks, Emmett B. Keeler, Denise R. Aberle, Arash Naeim, Timothy R. Church, Gerard A. Silvestri, Jeremy Gorelick, and Constantine Gatsonis for the National Lung Screening Trial Research Team

The authors examined cost-effectiveness in the National Lung Screening Trial (NLST), examining incremental cost-effectiveness ratio (ICER) and quality-adjusted life years (QALYs) associated with low dose CT screening. The ICER was $52,000 per life-year gained and the $81,000 per QALY gained. These values were very sensitive to variations in the screening algorithms.